Journal
AUTOPHAGY
Volume 19, Issue 3, Pages 758-767Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15548627.2022.2099206
Keywords
Autophagy; biomarkers; clinical treatments; COVID-19; neutrophil; NETosis
Categories
Ask authors/readers for more resources
This review summarizes the latest research progress of autophagy and NETosis in COVID-19 and provides an in-depth explanation of their underlying mechanisms. The relationship between autophagy and NETosis is explored, and potential treatment targets and options are discussed.
The COVID-19 pandemic has caused substantial losses worldwide in people's lives, health, and property. Currently, COVID-19 is still prominent worldwide without any specific drug treatment. The SARS-CoV-2 pathogen is the cause of various systemic diseases, mainly acute pneumonia. Within the pathological process, neutrophils are recruited to infected sites, especially in the lungs, for the first stage of removing invading SARS-CoV-2 through a range of mechanisms. Macroautophagy/autophagy, a conserved autodegradation process in neutrophils, plays a crucial role in the neutrophil phagocytosis of pathogens. NETosis refers to neutrophil cell death, while auto-inflammatory factors and antigens release NETs. This review summarizes the latest research progress and provides an in-depth explanation of the underlying mechanisms of autophagy and NETosis in COVID-19. Furthermore, after exploring the relationship between autophagy and NETosis, we discuss potential targets and treatment options. This review keeps up with the latest research on COVID-19 from neutrophil autophagy and NETosis with a new perspective, which can guide the urgent development of antiviral drugs and provide guidance for the clinical treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available